A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)
Primary Purpose
PTSD
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Riluzole
Sponsored by
About this trial
This is an interventional treatment trial for PTSD
Eligibility Criteria
Inclusion Criteria:
- Male or female subjects between the ages of 18-75 years;
- Able to provide written informed consent;
- Current Post Traumatic Stress Disorder, as determined by the Clinician Administered Scale for PTSD, or the presence of sub-threshold PTSD. Individuals with sub-threshold PTSD will be included at the discretion of the PI;
- Clinician Administered PTSD Scale (CAPS) score of 23 or higher;
- Be able to understand and speak English.
- Subjects taking FDA-approved antidepressant medications may enter the study if they have been on a stable dose for at least 4 weeks prior to starting the study drug.
Exclusion Criteria:
- Breastfeeding women and pregnant women, or women of child bearing potential who are not using a medically accepted means of contraception (to include oral, injectable, or implant birth control, condom, diaphragm with spermicide, intrauterine device, tubal ligation, abstinence, or partner with vasectomy);
- Current, ongoing serious suicidal risk as assessed by evaluating investigator or by scoring 5 or more on the item-10 of the MADRS.
- Unstable medical illness as determined by the investigator;
- Patients with schizophrenia or schizoaffective disorders (current or past);
- Substance use disorder during the 3 months prior to screening; except for Cannabis and Alcohol use Disorders.
- Clinical evidence of untreated hypothyroidism;
- Patients with any evidence of clinically significant liver abnormalities, or any liver transaminase level > 1.5 x ULN at initial screening, or > 5 x ULN during treatment;
- Axis II personality disorders that are the primary purpose of treatment, or would interfere with a patient's safety or compliance, as determined by the investigator during open-ended psychiatric interview;
- Patients currently being treated for a respiratory disorder (including asthma or COPD);
- For participants over the age of 60, evidence of dementia as determined by the St. Luis University Mental Status Exam (SLUMS; participants with total scores less than or equal to 20 will be excluded and referred to their Primary Care Physician for follow-up/dementia evaluation); Structured psychotherapy focused on treatment of PTSD is exclusionary unless the subject has had at least 8 weeks of treatment prior to starting the study medication;
Sites / Locations
- Clinical Neuroscience Division, National Center for PTSD
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Riluzole
Arm Description
Riluzole 50 mg orally twice per day
Outcomes
Primary Outcome Measures
Change in Clinician Administered PTSD Scale (CAPS)
The CAPS is a standardized clinician-rated instrument to assess the presence and severity of PTSD symptoms. The scores range from 0 (minimum) to 80 (mazimum). Higher scores reflect worse symptoms.
Secondary Outcome Measures
Post-Traumatic Stress Disorder Checklist (PCL)
Clinical Global Impressions Scale
Montgomery-Asberg Depression Rating Scale (MADRS)
Full Information
NCT ID
NCT02019940
First Posted
December 18, 2013
Last Updated
March 19, 2020
Sponsor
Yale University
Collaborators
National Center for PTSD
1. Study Identification
Unique Protocol Identification Number
NCT02019940
Brief Title
A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)
Official Title
An Investigation of the Effects of Riluzole in Patients With Post-Traumatic Stress Disorder (PTSD)
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
January 2020 (Actual)
Study Completion Date
January 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
National Center for PTSD
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This open label study will evaluate the safety and efficacy of riluzole in patients with PTSD. Patients will receive riluzole 50mg twice per day orally for 12 weeks as outpatient, with a one month follow up at week 16.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PTSD
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
18 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Riluzole
Arm Type
Experimental
Arm Description
Riluzole 50 mg orally twice per day
Intervention Type
Drug
Intervention Name(s)
Riluzole
Primary Outcome Measure Information:
Title
Change in Clinician Administered PTSD Scale (CAPS)
Description
The CAPS is a standardized clinician-rated instrument to assess the presence and severity of PTSD symptoms. The scores range from 0 (minimum) to 80 (mazimum). Higher scores reflect worse symptoms.
Time Frame
Change from baseline to 12 weeks
Secondary Outcome Measure Information:
Title
Post-Traumatic Stress Disorder Checklist (PCL)
Time Frame
12 weeks
Title
Clinical Global Impressions Scale
Time Frame
12 weeks
Title
Montgomery-Asberg Depression Rating Scale (MADRS)
Time Frame
12 weeks
Other Pre-specified Outcome Measures:
Title
Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR)
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female subjects between the ages of 18-75 years;
Able to provide written informed consent;
Current Post Traumatic Stress Disorder, as determined by the Clinician Administered Scale for PTSD, or the presence of sub-threshold PTSD. Individuals with sub-threshold PTSD will be included at the discretion of the PI;
Clinician Administered PTSD Scale (CAPS) score of 23 or higher;
Be able to understand and speak English.
Subjects taking FDA-approved antidepressant medications may enter the study if they have been on a stable dose for at least 4 weeks prior to starting the study drug.
Exclusion Criteria:
Breastfeeding women and pregnant women, or women of child bearing potential who are not using a medically accepted means of contraception (to include oral, injectable, or implant birth control, condom, diaphragm with spermicide, intrauterine device, tubal ligation, abstinence, or partner with vasectomy);
Current, ongoing serious suicidal risk as assessed by evaluating investigator or by scoring 5 or more on the item-10 of the MADRS.
Unstable medical illness as determined by the investigator;
Patients with schizophrenia or schizoaffective disorders (current or past);
Substance use disorder during the 3 months prior to screening; except for Cannabis and Alcohol use Disorders.
Clinical evidence of untreated hypothyroidism;
Patients with any evidence of clinically significant liver abnormalities, or any liver transaminase level > 1.5 x ULN at initial screening, or > 5 x ULN during treatment;
Axis II personality disorders that are the primary purpose of treatment, or would interfere with a patient's safety or compliance, as determined by the investigator during open-ended psychiatric interview;
Patients currently being treated for a respiratory disorder (including asthma or COPD);
For participants over the age of 60, evidence of dementia as determined by the St. Luis University Mental Status Exam (SLUMS; participants with total scores less than or equal to 20 will be excluded and referred to their Primary Care Physician for follow-up/dementia evaluation); Structured psychotherapy focused on treatment of PTSD is exclusionary unless the subject has had at least 8 weeks of treatment prior to starting the study medication;
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chadi Abdallah, MD
Organizational Affiliation
National Center for PTSD / Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinical Neuroscience Division, National Center for PTSD
City
West Haven
State/Province
Connecticut
ZIP/Postal Code
06516
Country
United States
12. IPD Sharing Statement
Links:
URL
http://www.ptsd.va.gov/
Description
National Center for PTSD
Learn more about this trial
A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)
We'll reach out to this number within 24 hrs